285 results about "Bone marrow mesenchymal stem cells" patented technology

The invention relates to a bone organ constructed based on oxygen-releasing immune hydrogel microspheres and a preparation method and application thereof. An oxygen release material, macrophages and bone marrow mesenchymal stem cells are loaded in the oxygen release immune hydrogel microspheres. And adding the oxygen-releasing immune hydrogel microspheres into a culture medium for culturing to obtain the bone organ constructed based on the oxygen-releasing immune hydrogel microspheres. The oxygen release material (CaO2-HAp) is entrapped in the hydrogel microspheres, so that continuous oxygen supply can be provided in a defect area, the low-oxygen environment is improved, the activity of osteoblasts is improved, osteogenic differentiation is promoted, macrophages are entrapped by the microspheres, the immune microenvironment is regulated and controlled, the release of proinflammatory cytokines is reduced, the osteogenic efficiency is improved, and bone defect repair is accelerated. The micro-fluidic technology is utilized to accurately control the size and shape of the microspheres, so that the microspheres can adapt to irregular bone defects, bone organs are formed through long-term in-vitro culture, and the biological activity and adaptability of the bone repair material are improved.

The invention relates to bionic matrix hydrogel for constructing bone organs and a preparation method of the bionic matrix hydrogel. The bionic matrix hydrogel is prepared from a bone acellular extracellular matrix, a salmon DNA (Deoxyribose Nucleic Acid) network and a calcium phosphate oligomer under the combination of photo-crosslinking and self-assembly physical crosslinking. The acellular extracellular matrix in the bionic matrix hydrogel can simulate organic components in natural bones, the calcium phosphate oligomer can simulate inorganic components in the natural bones, and sufficient phosphate ions can be provided for biomineralization due to introduction of a DNA network. The biomimetic matrix hydrogel can replace Matrigel to act in bone organoid culture, provide a living environment similar to bone tissue for three-dimensional culture cells, enhance substance exchange and signal transduction between cells, promote proliferation, adhesion and osteogenic differentiation of bone marrow mesenchymal stem cells, and further accelerate the process of biomineralization. The invention provides an optional new material for preparing the functional bone organ.

The present invention relates to the field of biomedical materials. Particularly provided is a DNA-silk fibroin composite hydrogel microsphere. The DNA-silk fibroin composite hydrogel microsphere is prepared from DNA and silk fibroin on the basis of the micro-fluidic technology by means of combination of self-assembly physical crosslinking and photo-crosslinking. The introduction of a silk fibroin network into the composite hydrogel microsphere can provide mechanical performance for a DNA hydrogel network and reduce the production cost. RGD can remarkably improve the cell loading capability of the microsphere. The hydrogel microsphere can simulate a microenvironment of cartilage tissue by means of three-dimensional loading of high-density cells, so as to enhance substance exchange and signaling between cells, and more effectively promote the proliferation and adhesion of bone marrow mesenchymal stem cells and regulating the chondrogenic differentiation, thus promoting cartilage regeneration and repair, and providing an available material for preparing medicaments or medical instruments for cartilage defect repair.

The invention relates to a cartilage organ constructed on the basis of a DNA-silk fibroin hybrid hydrogel sustained-release system as well as a preparation method and application of the cartilage organ. The DNA-silk fibroin hybrid hydrogel sustained-release system is a hydrogel system formed by printing a DNA-silk fibroin hybrid hydrogel sustained-release system premix solution through a digital light processing system, and the DNA-silk fibroin hybrid hydrogel sustained-release system premix solution contains DNA, silk fibroin, acryloylated RGD peptide, acryloylated polyethylene glycol NHS ester, glucosamine, TD-198946 and 2, 4, 6-trimethyl-1, 3-pentanediol. The invention discloses a lithium 2, 6-trimethylbenzoyl phosphate. Compared with the prior art, the glucosamine and the TD-198946 introduced into the DNA-silk fibroin hybrid hydrogel sustained-release system disclosed by the invention can be used for remarkably improving and promoting the cartilage differentiation efficiency of the bone marrow mesenchymal stem cells; the cartilage graft can be transplanted to a cartilage defect position as a cartilage graft to promote cartilage regeneration and repair.

Disclosed are methods of treating perianal fistula a subject by administering a therapeutic MSC secretome product made by a method comprising culturing bone marrow-derived MSCs under conditions that include oxygen tension below 5% and a culture media with a pH below 7.

The invention discloses composite gel for osteochondral repair as well as a preparation method and application of the composite gel. Main raw materials of the composite gel are regenerated silk fibroin (RSF) and recombinant humanized III-type collagen (rhCol-III), and auxiliary raw materials of the composite gel are sodium hyaluronate (HA), fibrinogen and thrombin. The preparation method comprises the following steps: firstly, mixing an RSF solution with an rhCol-III solution, obtaining RSF-rhCol particles through a freeze drying technology and mechanical pulverization, dispersing the particles in an HA solution to obtain composite gel, mixing the gel with a thrombin solution, catalyzing fibrinogen to be split and converted into fibrin by thrombin, and performing freeze drying to obtain the rhCol-RhCol-RhCol-RhCol-RhCol-RhCol-RhCol. And crosslinking the fibrous protein monomer to obtain the injectable composite gel preparation capable of immediately gelling. The prepared RSF-rhCol composite gel can adapt to a defect area, has a certain adhesion effect, has excellent biocompatibility, promotes migration of bone marrow mesenchymal stem cells, induces cell differentiation and promotes cartilage tissue regeneration.

The invention relates to the technical field of biomedical materials, and particularly discloses a preparation method of bionic hydrogel capable of bidirectionally inducing BMSCs (bone marrow mesenchymal stem cells) to promote epiphyseal plate repair through regulation and control mechanics, which comprises the following steps: step 1, mixing 10wt% of methacrylated gelatin, 10wt% of methacrylated decellularized cartilage matrix and 0.5 wt% of phenyl (2, 4, 6-trimethyl-1, 3-pentanediol) according to a ratio of the methacrylated gelatin to the methacrylated The preparation method comprises the following steps: respectively preparing methacrylated gelatin and methacrylated acellular cartilage matrix pre-polymerization solutions according to the concentration of (1, 2, 6-trimethylbenzoyl) lithium phosphate, and carrying out 37 DEG C constant-temperature dark water bath until the methacrylated gelatin and methacrylated acellular cartilage matrix pre-polymerization solutions are completely dissolved for later use; and 2, mixing the 10 wt% methacrylated decellularized cartilage matrix prepolymer solution and the 10 wt% methacrylated gelatin prepolymer solution according to a ratio of 3: 7 to obtain a methacrylated gelatin / methacrylated decellularized cartilage matrix prepolymer solution, carrying out cross-linking under blue light with a wavelength of 365 nm for 5-20 s, and carrying out drying to obtain the methacrylated gelatin / methacrylated decellularized cartilage matrix. The methylacryloylated gelatin / methylacryloylated acellular cartilage matrix composite hydrogel is prepared from the methylacryloylated gelatin and the methylacryloylated acellular cartilage matrix.

Disclosed are methods of improving perioral and face fat graft retention in a subject by administering a therapeutic MSC secretome product made by a method comprising culturing bone marrow-derived MSCs under conditions that include oxygen tension below 5% and a culture media with a pH below 7.

The invention belongs to the technical field of biological medicine, and discloses a high-efficiency vascular endothelial cell targeting vesicle system, which is prepared from hemangioma stem cell derived exosome HemSCs-Exos and bone marrow mesenchymal stem cell derived apoptotic small body BMSCs-ABs, and is characterized in that the endothelial cell targeting vesicle system is prepared from the hemangioma stem cell derived exosome HemSCs-Exos and the bone marrow mesenchymal stem cell derived apoptotic small body BMSCs-ABs; meanwhile, the invention further discloses a preparation method of the vesicle system and application of the vesicle system in promoting proliferation and migration of endothelial cells. Different from existing targeting modification, the ingenious targeting relationship between the BMSCs-ABs and the endothelial cells belongs to non-special modification combination, and is simple and efficient; the fusion between the double EVs has the characteristic of realizing '1 + 1gt, 2', not only retains the treatment components of the HemSCs-Exos and the BMSCs-ABs, but also the fused eHEs has remarkable cell specificity distribution, and the fusion mode is simple and stable.

The invention relates to a two-phase hydrogel system based on space-time gradient regulation and control as well as a preparation method and application of the two-phase hydrogel system. The biphase hydrogel system can also be expressed as a GelMA composite hydrogel scaffold of a porous structure, the whole biphase hydrogel system is of a core-shell structure, the inner layer core mineralizes SilMA hydrogel microspheres, the porous GelMA hydrogel scaffold is used as an outer layer, and the angiogenesis promoting factor dimethyl oxalaminoacetic acid, the human umbilical vein endothelial cells and the bone marrow mesenchymal stem cells are loaded on the outer layer. Wherein the inner-layer core mineralized SilMA hydrogel microspheres realize continuous release of osteogenesis signals by slowly releasing nHAp, and the outer-layer porous GelMA hydrogel stent releases DMOG by rapid degradation to realize early angiogenesis, so that space-time coupling construction of blood vessels and bone tissues is realized. Through differential degradation characteristics of inner and outer layers of hydrogel, precise time sequence cooperative regulation and control of angiogenesis and bone tissue remodeling can be realized, and the bionic property and function integration capability of a vascularized bone organ structure can be improved, so that the clinical transformation potential of the vascularized bone organ structure is improved.

The invention relates to the technical field of biological medicine, in particular to a chronic disease treatment composition based on mesenchymal stem cells and a preparation method thereof, and the chronic disease treatment composition comprises the mesenchymal stem cells; the mesenchymal stem cells are adipose mesenchymal stem cells, dental pulp mesenchymal stem cells and bone marrow mesenchymal stem cells. According to the invention, the culture medium of the adipose-derived mesenchymal stem cells is improved, and the prepared adipose-derived mesenchymal stem cells have higher proliferation activity. Meanwhile, through experimental tests, the adipose-derived stem cells can inhibit proliferation of the prostatic hyperplasia epithelium BPH-1 cells and remarkably promote apoptosis of the prostatic hyperplasia epithelium BPH-1 cells, a new direction is provided for treatment of prostatic hyperplasia, and the adipose-derived stem cells have huge application value.

The invention provides application of a deacetylase inhibitor or a derivative thereof and application of a pharmaceutical composition, and belongs to the technical field of biology. The application of the deacetylase inhibitor or the pharmaceutically acceptable derivative thereof comprises the application of the deacetylase inhibitor for preparing a medicine for treating osteoporosis; wherein the deacetylase inhibitor is used for inducing histone acetylation in a cell nucleus. By inducing acetylation of histone in a cell nucleus, the differentiation direction of the bone marrow mesenchymal stem cells is accurately and efficiently controlled, and a treatment scheme for osteoporosis related diseases is developed.

The invention relates to a time sequence degradable orthopedic implant material which comprises a base material and a biodegradable coating formed on the surface of the base material, the surface of the base material is provided with a nanocone array microstructure, the biodegradable coating takes a biodegradable polymer as a matrix and loads a metal element for promoting bone repair, and the metal element is a metal element for promoting bone repair. And the surface of the biodegradable coating is also connected with an anti-inflammatory active factor. According to the invention, grafted anti-inflammatory active factors are matched with the biodegradable coating loaded with metal elements for promoting bone repair, and the sequential active regulation and control of the biological effect of the micro-morphology on the surface of the base material cope with effector cells in different repair stages; the time sequence regulation and control on the macrophage inflammation phenotype and bone marrow mesenchymal stem cell osteogenic differentiation in different stages of bone repair are realized, so that each stage of bone tissue repair is matched, and bone repair and osseointegration are promoted.

The application relates to a cartilage organoid based on a DNA-silk fibroin hybrid hydrogel sustained-release system and a preparation method and application thereof. The DNA-silk fibroin hybrid hydrogel sustained-release system is a hydrogel system after a DNA-silk fibroin hybrid hydrogel sustained-release system premixing solution is printed through a digital light processing system, wherein the DNA-silk fibroin hybrid hydrogel sustained-release system premixing solution contains DNA, silk fibroin, acrylated RGD peptide, acrylated polyethylene glycol NHS ester, glucosamine, TD-198946 and 2,4,6-trimethylbenzoyl lithium phosphate. Compared with the prior art, the glucosamine and TD-198946 introduced in the DNA-silk fibroin hybrid hydrogel sustained-release system can significantly improve the cartilage differentiation efficiency of bone marrow mesenchymal stem cells; and the application can be transplanted to a cartilage defect as a cartilage graft to promote cartilage regeneration and repair.

The invention belongs to the technical field of biological medicines, and particularly relates to a recombinant polypeptide for improving the activity of bone marrow mesenchymal stem cells and application of the recombinant polypeptide. The amino acid sequence of the recombinant polypeptide is as shown in SEQ ID NO.3. The recombinant polypeptide is obtained by integrating an extracellular matrix amino acid sequence and a heparin amino acid sequence. The recombinant polypeptide provided by the invention can promote the expression of the Ki67 gene and improve the proliferative activity of the bone marrow mesenchymal stem cells, also has the effect of inhibiting the replicative aging of the bone marrow mesenchymal stem cells, and has a wide application prospect.

The application discloses a flavonoid compound in eaglewood as well as a preparation method and application of the flavonoid compound, and relates to the technical field of medicines. The application extracts and separates a new compound from natural eaglewood, and the new compound is used in the preparation of anti-osteoporosis drugs. The compound is detected in vitro to obtain an induction effect of the compound on the differentiation of bone marrow mesenchymal stem cells (BMSCs) into osteoblasts, so as to affect the formation of osteoclasts. Meanwhile, the compound can promote the bone development of zebra fish through RT-qPCR detection, which indicates that the compound has anti-osteoporosis activity. The separation method of the compound is simple and easy to operate.

The utility model discloses a centrifugal device for extracting mesenchymal stem cells, and relates to the technical field of mesenchymal stem cell analysis, the centrifugal device comprises a device body, a feed inlet and a lifting rod, the inner side of the device body is provided with a lifting plate, and the middle position above the lifting plate is provided with a driving motor; the output end of the driving motor is connected with a centrifugal box through a driving shaft, test tubes are installed above sponge pads, the outer walls of the two sides of the device body are provided with installation holes, ice boxes are installed on the inner sides of the installation holes, and fans are installed above the ice boxes. According to the test tube cooling device, ice blocks are placed in the ice box, then the ice box is installed in the installation hole, the draught fan works to blow air to the ice blocks in the ice box, formed cold air is exhausted through the multiple air outlet pipes, the cold air is exhausted into the device body, test tubes can be cooled conveniently, and the problem that the test tubes are inconvenient to cool is solved.

The invention discloses a bone immunoregulation osteogenesis promoting method of PLL-MgBGs / SF frozen gel and an osteogenesis capability detection method of the PLL-MgBGs / SF frozen gel. The bone immunoregulation osteogenesis promoting method comprises the following steps: preparing a magnesium-doped bioactive substance MgBGs; the preparation method comprises the following steps: preparing PLL-MgBGs nano particles; pLL-MgBGs / SF frozen gel is prepared; a sterile PLL-MgBGs / SF frozen gel leaching solution is prepared; the method comprises the following steps: inoculating macrophages (RAW264.7) into a 48-pore plate, culturing by using a complete culture medium containing LPS (100 ng / mL), and then culturing by using a complete culture medium containing a PLL-MgBGs / SF frozen gel leaching solution. The PLL-MgBGs / SF freezing gel has the advantages that the prepared PLL-MgBGs / SF freezing gel is excellent in water response shape memory ability, capable of releasing various active ions such as Mg < 2 + >, Ca < 2 + > and SiO4 < 4->, remarkable in potential in immunoregulation and bone repair, capable of being implanted into bone defects in an injection mode to fill the bone defects, capable of being rapidly matched with irregular bone defects and capable of improving the bone repair effect. According to the present invention, the problem of insufficient matching of the traditional bone scaffold and the irregular defect site is solved, the excellent mechanical stability and the excellent structure retention can be represented during the degradation process, the good supporting ability is provided in the bone defect region, the polarization of the macrophage can be adjusted to be the M2 type, and the collection, the proliferation and the osteogenic differentiation of the bone marrow mesenchymal stem cells (BMSCs) can be promoted.

The invention discloses a long-chain non-coding RNA (Ribonucleic Acid) and application thereof in regulating osteogenic differentiation of bone marrow mesenchymal stem cells. It is found that overexpression of long-chain non-coding RNA (lncRNA Gm20628) with the nucleotide sequence shown in SEQ ID NO.1 in bone marrow mesenchymal stem cells can effectively promote osteogenic differentiation of the bone marrow mesenchymal stem cells, and then bone defect repair of a mouse with skull injury is promoted. Therefore, the invention provides application of the expression promoter of the lncRNA Gm20628 in preparation for enhancing bone regeneration, repairing bone defects and treating osteoporosis and bone formation disorder related diseases. The method is not only beneficial to treatment of diseases related to the bone marrow mesenchymal stem cells, but also beneficial to construction of bone organs.

The invention belongs to the technical field of biotechnology and tissue engineering, and particularly relates to application of pilose antler bud cell secretions in preparation of anti-osteoporosis drugs. The pilose antler bud cell secreta is obtained by adopting gradient centrifugation, and cell experiments show that the pilose antler bud cell secreta provided by the invention has the effect of promoting osteogenic differentiation of cells; animal experiment results show that the cornu cervi pantotrichum bud cell secreta provided by the invention can significantly improve the bone mineral density, bone volume fraction, bone trabecula number, bone trabecula thickness, bone trabecula separation degree and cortical bone mineral density of mice, increase the bone trabecula area of primary osteogenesis and secondary osteogenesis centers of the mice, improve osteoporosis symptoms of the mice, and improve osteoporosis of the mice. The effect is obviously better than that of bone marrow mesenchymal stem cell secretions, part of indexes are equivalent to the treatment effect of diphosphates, and the antler bud cell secretions provided by the invention can be used for preparing medicines for preventing, relieving or treating osteoporosis.

The invention belongs to the technical field of medicines, and particularly relates to bletilla striata polysaccharide hydrogel as well as a preparation method and application thereof. The BSP-MA / HA-NB hydrogel is prepared by screening the variety, dosage and preparation process of each component in the hydrogel, and the hydrogel is prepared from the following raw materials: methacrylated bletilla striata polysaccharide, o-nitrobenzaldehyde modified hyaluronic acid and the like. The adhesive property and the mechanical property of the hydrogel are obviously improved; the long-acting slow-release effect of the medicine components is achieved, the proliferation activity and migration ability of the bone marrow mesenchymal stem cells are promoted, and the bone marrow mesenchymal stem cells have good application prospects in the aspect of bone defect repair treatment.

The invention belongs to the field of application materials, and particularly relates to Ber-ApoEVs and preparation and application thereof.The Ber-ApoEVs comprise ApoEVs and Ber supported by the ApoEVs, the ApoEVs are bone marrow mesenchymal stem cell-derived apoptosis vesicles, and the Ber is berberine and a derivative thereof. Researches show that brand new Ber-ApoEVs play a synergistic neuroprotective role in the aspects of regulating and controlling polarization of microglial cells, release of inflammatory factors, p38 / MAPK signals and the like, neuroinflammation caused by retinal ischemia reperfusion (IR) can be relieved, retinal neuron apoptosis can be inhibited, and the Ber-ApoEVs can be used for treating glaucoma.

The invention provides a developmental growth plate layered stent as well as a preparation method and application thereof, and belongs to the technical field of bone tissue engineering materials. The developmental growth plate layered stent provided by the invention is divided into three layers, the upper layer is a cartilage cell layer, the middle layer is a blood vessel barrier layer, and the lower layer is an ossification layer. The blood vessel barrier layer can be used as biological glue to bond the upper layer and the lower layer, so that the composite stent is stable in structure and not easy to break; the upper layer contains bone marrow mesenchymal stem cells (BMSCs), and the middle layer and the lower layer are free of cells. Under the condition of in-vitro chondrogenesis induction culture, the BMSCs on the upper layer can penetrate through the middle layer and be colonized on the lower layer, and in the process, part of the BMSCs can be differentiated into cartilage cells. The middle layer containing the platelet reaction protein 1 (TSP1) has a specific intervention effect on cell migration, which is expressed by inhibiting the migration of vascular endothelial cells, but has no influence on the migration of the BMSCs.

Provided is a use of dipsaci radix-derived extracellular vesicle-like nanoparticles (DREVNs) in preparation of a drug for preventing or treating orthopedic diseases. In this application, EVs are creatively extracted from dipsaci radix and purified, and the physiological efficacy of the EVs is studied. It has been found that the EVs can be fully internalized by bone marrow mesenchymal stem cells (BMSCs), can promote the osteogenic differentiation of BMSCs by activating a BMP2 / Smads signaling pathway, promote the calcified nodule formation in BMSCs, and promote the expression of osteogenic differentiation-associated genes ALP, OCN, RUNX2, and COL1, and have bone targetability in vivo. The EVs can be intragastrically administered to alleviate the osteoporosis (OP) in postmenopausal mice. Therefore, the EVs have the potential of being used to prepare drugs for preventing or treating orthopedic diseases, and provide a new strategy for the prevention or treatment of orthopedic diseases.

The invention belongs to the technical field of pet bone joint prevention and treatment, and particularly provides a stem cell exosome and application thereof in preparation of medicine for preventing and treating pet bone joint diseases. The RANKL monoclonal antibody 5F16 and the mesenchymal stem cell exosome are combined for the first time to be used for preventing and treating the bone joint diseases of the pets, and test analysis shows that the preparation can effectively reduce the levels of IL-1beta, TNF-alpha and IL-6 in serum of the pets caused by bone joint injuries, inhibit secretion of the IL-1beta, the TNF-alpha and the IL-6, repair the bone joint injuries, improve and promote cartilage tissue repair, prevent and treat the bone joint diseases of the pets and prevent and treat the bone joint diseases of the pets. Good application prospects are realized.

This invention discloses a composite microsphere loaded with ZIF-8 nanoparticles and stem cell extracellular vesicles, its preparation method, and its applications. The composite microsphere comprises a hydrogel matrix microsphere, and ZIF-8 nanoparticles and small extracellular vesicles derived from bone marrow mesenchymal stem cells uniformly dispersed and encapsulated within the hydrogel matrix microsphere. This invention integrates ZIF-8 nanoparticles and stem cell-derived sEVs into injectable, photocurable GelMA microspheres, constructing an integrated delivery platform capable of sequential release and multi-stage synergistic effects. This platform successfully integrates and leverages three major functions: immunomodulation, stem cell recruitment, and cartilage-induced differentiation, ultimately achieving high-quality functional healing of the tendon-bone interface at both histological and biomechanical levels, providing a highly promising new strategy for the regeneration and repair of interfacial tissues in the musculoskeletal system.

The invention provides hydrogel, a porous titanium / hydrogel composite implant material and a preparation method of the porous titanium / hydrogel composite implant material. The hydrogel is obtained by photo-crosslinking and curing a hydrogel precursor solution containing acrylated beta-cyclodextrin, acrylated alendronate sodium, gelatin and a chemotactic factor. The hydrogel has a porous network structure, high elastic modulus, high fatigue resistance and excellent biocompatibility, and also has the capability of recruiting bone marrow mesenchymal stem cells (BMSCs) and the capability of promoting osteogenic differentiation of the BMSCs; the porous titanium / hydrogel composite implant material prepared from the hydrogel can effectively promote the growth of new bone tissues, has excellent osseointegration capability, obviously improves the osteogenesis repair effect and the osseointegration effect, provides a new treatment approach for the repair treatment of segmental bone defects, and has important medical significance.

The application provides a preparation method of a high-efficiency piezoelectric coating on a titanium implant surface. The preparation method of the application uses a hydrothermal treatment and an in-situ piezoelectric deposition technology to in-situ synthesize a nano strontium titanate-noble metal piezoelectric coating on the titanium implant surface. The coating can generate a piezoelectric potential and active oxygen through ultrasonic driving to degrade extracellular polymers and kill bacteria. In addition, the piezoelectric coating can also promote the osteogenic differentiation of bone marrow mesenchymal stem cells under piezoelectric stimulation, and finally realize the effects of bioactivity, long-acting drug-resistant bacteria and high-efficiency bone integration in the body. The application can provide a new surface treatment technology and research idea for controlling the drug-resistant bacteria infection on the implant surface, help to break through the limitations of the existing theory and technology in removing bacterial infection on the titanium implant surface, and provide beneficial guidance for the control of bacterial biofilm on other parts and the prevention and treatment of related infectious diseases.

The invention provides application of linariin-6-O-glucoside in preparation of a product for preventing and treating osteoporosis, and relates to the field of biological medicine. According to the invention, dyeing experiments of alkaline phosphatase, alizarin red and tartaric acid resistant acid phosphatase prove that the sesaminin-6-O-glucoside has affinity for FPPS receptors, has the capability of promoting bone marrow mesenchymal stem cells to form bone cells, is superior to that of bisphosphate, and can inhibit the generation of osteoclasts; microCT (micro computed tomography) detection results show that the sesaminin-6-O-glucoside has the effect of relieving the osteoporosis and can promote the formation of bone trabecula. According to the application disclosed by the invention, it is proved for the first time that the sesaminin-6-O-glucoside has the effect of resisting osteoclast formation, and meanwhile, the sesaminin-6-O-glucoside also has a better osteogenesis effect, so that a basis is provided for developing the sesaminin-6-O-glucoside as a potential medicine for treating osteoporosis.

The invention provides application of an FZD4 gene. The FZD4 gene is used for regulating osteogenic differentiation and mineralization of chicken bone marrow mesenchymal stem cells. The FZD4 gene in the chicken bone marrow mesenchymal stem cells is over-expressed and is used for promoting osteogenic differentiation and mineralization of the chicken bone marrow mesenchymal stem cells; or / and the FZD4 gene in the chicken bone marrow mesenchymal stem cells is knocked down to inhibit osteogenic differentiation and mineralization of the chicken bone marrow mesenchymal stem cells; the nucleotide sequence of the coding region of the FZD4 gene is as shown in SEQ ID NO. 1. According to the invention, the positive regulation effect of the FZD4 gene in osteogenic differentiation of chicken bone marrow mesenchymal stem cells is determined for the first time, the blank of a bone regulation mechanism of the poultry FZD4 gene is filled, and a new biological preparation target is provided for prevention and treatment of poultry bone diseases; the FZD4 gene can also be used as a molecular marker for breeding chicken varieties with high bone strength.